| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| MRK | Merck & Company, Inc. | $70.42 | $187.28B | N/A |
Stocks making the biggest moves premarket: MRK, PFE, AAPL, UAA, FB, BA & more
https://www.cnbc.com/2018/05/01/stocks-making-the-biggest-moves-premarket-mrk-pfe-aapl-uaa-fb-ba-more.html
May 01, 2018 - Names on the move ahead of the open.
18
Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today
https://www.fool.com/investing/2017/09/12/heres-why-advaxis-inc-stock-is-getting-pummeled-to.aspx?source=iedfolrf0000001
Sep 12, 2017 - Despite a lack of particularly damaging news, investors are losing patience with this biotech.
17
Stocks making the biggest moves premarket: BA, NVDA, MRK, DIS & more
https://www.cnbc.com/2018/03/12/stocks-making-the-biggest-moves-premarket-ba-nvda-mrk-dis-more.html
Mar 12, 2018 - Names on the move ahead of the open.
16
The IDO-Inhibitor Race Is On to Improve Cancer Treatment
https://www.fool.com/investing/2017/04/13/the-ido-inhibitor-race-is-on-to-improve-cancer-tre.aspx?source=iedfolrf0000001
Apr 13, 2017 - NewLink Genetics and Incyte Corporation's IDO-inhibitors could be the next big advance in cancer treatment.
13
10 Reasons Merck Could Be the World's Most Perfect Stock
https://www.fool.com/investing/2017/04/21/10-reasons-merck-could-be-the-worlds-most-perfect.aspx?source=iedfolrf0000001
Apr 21, 2017 - Merck may be a picture-perfect stock for long-term investors to consider buying.
13
Bleak Outlook for Big Drug Makers
https://www.wsj.com/articles/bleak-outlook-for-big-drug-makers-1493051153?mod=rss_markets_main
Apr 25, 2017 - Without price increases or deals to boost earnings, the pharmaceuticals sector faces a weak earnings season.
9
5 Great Things About Merck & Co.'s Q1 Results
https://www.fool.com/investing/2017/05/02/5-great-things-about-merck-cos-q1-results.aspx?source=iedfolrf0000001
May 02, 2017 - Merck handily beat expectations with its Q1 results. Here's how the drugmaker did it.
9
Here Are the Big Pharma Stocks to Own Based on R&D Spending
https://www.fool.com/investing/2017/08/27/here-are-the-big-pharma-stocks-to-own-based-on-r-2.aspx?source=iedfolrf0000001
Aug 27, 2017 - Roche, Novartis, Pfizer, Johnson & Johnson, and Merck are investing the heaviest in R&D. That could bode well for these big pharma stocks.
7
This Simple Step Can Make Diabetes Patients Healthier -- and Possibly Wealthier
https://www.fool.com/investing/2017/08/29/this-simple-step-can-make-diabetes-patients-health.aspx?source=iedfolrf0000001
Aug 29, 2017 - A study by Express Scripts points to how diabetes patients can avoid ER visits and hospital stays while potentially keeping more money in their pockets.
7
Better Buy: Merck & Co. Inc. vs. Johnson & Johnson
https://www.fool.com/investing/2017/04/19/better-buy-merck-co-inc-vs-johnson-johnson.aspx?source=iedfolrf0000001
Apr 19, 2017 - Does Merck's sizzling-hot cancer drug Keytruda give it a leg up over longtime winner Johnson & Johnson?
6